Before Pfizer closed its takeover, Metsera reported weight loss of up to 14.1% in a phase 2b trial of the weekly regimen.

Pfizer's stock has risen off its lows, but remains 50% below its 2021 highs.

A long-acting shot Pfizer got through a buyout of Metsera appeared “slightly inferior” to Lilly’s market-leading Zepbound in a Phase 2 trial, one analyst said.

Pfizer reported strong mid-stage weight loss trial results for its monthly obesity drug and posted fourth-quarter earnings ...

Pfizer reported that its newly acquired weight loss drug showed promise as a monthly treatment, though the field is growing ...

Pharmaceutical company’s stock price move diverges from rival Merck as both groups bolster new treatment pipelines ...